Call

Close
Contact us.
Technical Support
support@notalvision.com
Get Updates

Close

Stay up to speed

Learn more about ForeseeHome, request a rep visit, and get updates when new information becomes availlable.

Get Updates

Setup and daily tests are quick and easy for patients;
you control how alerts are managed6

  • The patient uses a mouse to click where a bump or wave in the dotted line appeared on the screen

1

  • ForeseeHome uses PHP to detect tiny changes in the central visual field, including metamorphopsia and scotoma

2

  • The patient’s daily test results are automatically sent to Notal Vision

3

Timely alerts can lead to earlier treatment6

Sample Monthly Report

  • You are alerted when a significant change from baseline occurs, which may indicate AMD progression
  • Monthly reports are emailed to your practice. Testing results are available 24/7 via the Notal Vision portal
    • You customize how alerts are shared; they can be sent to you or anyone in your office via email
    • Alerts can also be sent to patients with your written consent
  • In the study, 21% of patients experienced alerts from significant changes in (central and/or paracentral) metamorphopsia that did not result in a diagnosis of wet AMD
    • ForeseeHome measures statistically significant changes in metamorphopsia. Alerts that do not lead to a wet AMD diagnosis may still indicate other significant changes in the disease status that need to be addressed clinically
  • During the ForeseeHome test, a series of dotted lines flash on the screen and disappear
  • Using a mouse, the patient clicks where he/she saw a distortion (such as a bump or wave) on the dotted line
  • The test takes about 3 minutes per eye
  • Once the test is complete, the data are automatically transmitted to the Notal Vision Data Monitoring Center

The patient uses a computer mouse to click where a bump or wave in the dotted
line has appeared on the screen.

WATCH DEMONSTRATIONThe technology behind the program

Ordering ForeseeHome is simple

First, identify appropriate patients

  • Best corrected vision of 20/60 or better
  • Patients with intermediate dry AMD at risk for progression to wet AMD

New prescribers

  • Read the Physician Responsibilities Description information for ordering ForeseeHome for your patient
  • Complete the Online Submission Form to become a ForeseeHome ordering clinic. This is a simple form that informs us of prescribers, points of contact, and where to send testing and alert information for your enrolled ForeseeHome patients
  • Once you have completed the Online Submission Form you will receive a welcome email from Notal Vision, maker of ForeseeHome, and you can begin prescribing.

Current prescribers

  • If you do not have an order form, print and complete the ForeseeHome Order Form. Please make a copy of the completed order form for your patient to take home
  • Fax the completed form to Notal Vision at 1-888-341-9400
  • Instruct your patient that they will receive a call from Notal Vision to verify Medicare or other insurance coverage and complete enrollment
  • Patients should also be recommended to contact Notal Vision at 1-888-910-2020 once they have received your order
  • We will send the ForeseeHome device to your patient and provide support to begin testing

Once we receive your order form, we’ll verify the patient’s insurance coverage

We’ll contact the patient and arrange delivery and personalized setup support for the ForeseeHome device

Patients and caregivers can call Notal Vision toll-free at 1-888-910-2020 at any time after you submit the order

Patients and caregivers can call Notal Vision at
1-888-910-2020 any time after receiving your request form

AMD=age-related macular degeneration; PHP=preferential hyperacuity perimetry.FORESEEHOME IS COVERED BY MEDICARE

Web Privacy Policy Notice of Privacy Policy Patents NotalVision.com Contact Us References Order Form

FDA Indication for Use

The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration, as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

The ForeseeHome AMD Monitoring Program is only available by physician order and is intended to be used as an addition to regular eye exams.

The technical component of the ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with dry AMD who are at risk of developing wet AMD. Please refer to your local Medicare Administrative Contractor (MAC) for which the ordering physician resides concerning coverage availability for the physician professional services component of the test.